AHSCT is a standard of care of RRMS

This is very important statement from ASBMT (THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION) – which considers AHSCT a standard of care in Multiple Sclerosis. This is pivotal statement in the care of MS as for the first time AHSCT is acknowledged not as clinical option but as a proven standard.

 

“Review of recent literature identified eight retrospective studies, eight clinical trials, and three meta-analyses/systematic reviews. In aggregate, these studies indicate that AHCT is an efficacious and safe treatment for active relapsing forms of MS to prevent
clinical relapses, MRI lesion activity, and disability worsening, and to reverse disability, without unexpected adverse events. Based on the available evidence, the ASBMT recommends that treatment-refractory relapsing MS with high risk of future disability be considered a “standard of care, clinical evidence available” indication for AHCT.”

https://www.ncbi.nlm.nih.gov/pubmed/30794930?fbclid=IwAR0TH3vOcr_g3T5KS7KkhJRpfrLP8oZ7LypSbQHBMGgeqHg6GcxNR2_vZao

Przechwytywanie

 

 

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s